Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 166 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Oura Digital Twin Dashboard

Oura Gen 4: 2026-01-08 to 2026-08-28 (233 unique days, 271 sleep periods) · 10/10 analysis modules loaded · Ruxolitinib 10 mg BID from 2026-03-16
POST-HSCT BIOMETRIC MONITORING

Consumer wearable suggests a physiological shift after JAK inhibitor start
exploratory N=1 monitoring in a confounded window

+15.8
HRV shift
ms (pre to post)
-14.2
Resting HR shift
bpm (pre to post)
233
Days
modelled
166
Post-drug
days observed
Oura Ring Gen 4 · 233 days · 10/10 analysis modules · Ruxolitinib 10 mg BID from 2026-03-16
Pre-Ruxolitinib to Post-Ruxolitinib
67 days (73 sleep periods) vs 166 days (198 sleep periods)
Key Finding
Analysis modules detected multiple biosignal shifts after ruxolitinib initiation, but the 166-day post-intervention window remains too short for strong causal claims. 0/0 CausalImpact streams reach raw p<0.05; 0/0 survive FDR correction. Separate UKF comparisons: Cardiac Reserve shift p<0.001, Sleep Quality shift p<0.001.
Temperature
N/A
No data
HRV (RMSSD)
20.6ms
vs healthy 42-49 ms | Kleiger 1987 / Bigger 1992
Resting HR
75bpm
IST threshold: 90 bpm
SpO2
95.7%
BOS risk: MODERATE (37/100)
Sleep Efficiency
75%
Below 85% threshold
Autonomic Tone
0.00SD
UKF state | improved | p<0.001
GVHD Score
20/100
7d avg: 30
Anomaly Days
24/271
Feb 9 detected (24 anomaly days, N=1)

Interrupted Time Series: Temperature Response

CausalImpact BSTS

Treatment Effect Sizes

CausalImpact + UKF

Disease State Trajectory

rSLDS 4-State Model

Anomaly Detection

5-Algorithm Ensemble

Composite Biomarker Trends

6 Biomarkers

SpO2 & BOS Risk

Pulmonary Screening

Combined Biosignal Timeline

5-Channel View

Heart Rate Terrain Map

3D Surface

Phase Space Reconstruction

Nonlinear Dynamics

Sleep Architecture Heatmap

Epoch-Level

Circadian Rhythm Analysis

Cosinor Model
Methodology & Data Provenance
Data Source
Oura Ring Gen 4 (continuous PPG, accelerometry, thermometry)
Volume
152,386 HR readings · 19,373 HRV samples · 22,407 sleep epochs
Analysis Pipeline
CausalImpact (BSTS) · Unscented Kalman Filter (5 latent states) · rSLDS (4 disease states) · 5-algorithm anomaly ensemble · 6 composite biomarkers · Chronos-2 / ARIMA forecasting
Sleep Architecture
Deep: 15.2% Light: 52.0% REM: 13.0% Awake: 19.8%
For research and clinical discussion only. Not a diagnostic tool. All p-values are exploratory.